Indonesian Ministry of Health Delegation Visits RuiXin Medical to Explore Collaboration in Cardiovascular Precision Diagnosis and Treatment
RaysightMed
Medical Imaging Product Developer
On September 29, 2025, Dr. L. Rizka Andalucia, Director General of the Ministry of Health (MOH) of the Republic of Indonesia, visited RaysightMed.In-depth discussions on the cooperation directions in areas such as medical innovation, technology export, and market access. During the visit, Zheng Lingxiao, founder and CEO of RaysightMed, along with the core management team, warmly welcomed the delegation led by the Director-General and engaged in in-depth exchanges.
Bilateral Talks:
Fully Discuss Key Issues, Lay Foundation for Future Cooperation
At the beginning of the talks,RaysightMed Founder and CEO, Zheng LingxiaoFirst introduced the company's development history, core products, and the original intention of being committed to improving the current state of diagnosis and treatment of cardiovascular diseases through original technology. He mentioned,RaysightMed is committed to providing the world's leading AI + surgical robot precision diagnosis and treatment platform for cardiovascular and cerebrovascular diseases in clinical settings, offering a full-course precision diagnosis and treatment solution covering "preoperative assessment - intraoperative diagnosis and intelligent treatment - postoperative intelligent management."。
When introducing the company's product solutions, Zheng Lingxiao pointed out that the company has developed and launchedAI-Driven One-Stop Coronary Functional Macro FFR + Micro IMR Assessment System AngioQFA, equipped with self-developed AI, 3D simulation, and connected sensor chip technology, is based on coronary angiography images. A single analysis can simultaneously obtain the patient's coronary blood flow reserve fraction (FFR) and microcirculatory resistance index (IMR), enabling non-invasive, precise, and comprehensive evaluation of the impact of coronary stenosis on myocardial blood supply and vascular microcirculation function in just 5 minutes.。Results from prospective clinical studies show that the FFR and IMR values measured by RaysightMed's AngioQFA are in good agreement with invasive gold standard results, with accuracy, sensitivity, and specificity all exceeding 95%, placing it at the top level in the industry.Currently, the technology and effectiveness of RaysightMed's AngioQFA have been recognized by dozens of well-known experts in China and have demonstrated significant clinical value in dozens of hospitals.。
Subsequently, co-founder and chief scientist Hongzhi Lan provided a detailed introduction to the "Precision Computer-Aided Design (CAD) Functional Diagnostic Solution," emphasizing how artificial intelligence enhances the accuracy and efficiency of cardiovascular assessments. First, he introduced the market status of the industry to the attendees, pointing out that pressure wire-based FFR has become the gold standard for evaluating coronary ischemia, but the use of FFR and IMR is currently relatively limited. Therefore, RaysightMed has developed the coronary functional evaluation systems AngioQFA and RuiXin-FFR through its self-researched innovative technologies.
He emphasized that RuiXin-FFR, developed by RaysightMed, is the world's only platform for assessing blood supply function based on both "morphology" and "functionality" that has obtained dual certifications from China’s NMPA and the EU MDR CE. It is also China's first CT-FFR product based on 3D-CFD (Computational Fluid Dynamics) technology. He then introduced the technical principles, core functions, technological advantages, and representative cases of the two products. When discussing clinical benefits, he mentioned: "RaysightMed's AngioQFA offers higher precision and automation, helping doctors achieve lower radiation exposure, while the RuiXin-FFR will significantly reduce medical costs for hospitals and patients.。”
Next, Co-founder and CTO Ma Jun brought a presentation on the fully automatic AI vascular interventional surgery robot. Currently, the field of vascular intervention urgently needs to address issues such as doctors' radiation exposure, the burden of wearing lead aprons, long learning curves, and the standardization of surgeries. In August this year, RaysightMed launched a fully automatic AI vascular interventional surgery robot. Equipped with a complete product form including end-effector mechanisms, robotic arms, and master control systems, it is based on an AI and robotics-driven automated PCI surgical technology framework. This highly integrated intelligent system forms a fully automatic diagnosis and treatment platform.Aiming to achieve precise and efficient PCI surgery through advanced natural language processing, deep learning, and robot control technologies, realizing the intelligence and automation of surgical operations.. This product not only improves the efficiency and success rate of surgeries but also reduces the burden on surgeons and lowers surgical risks.
RaysightMed's Fully Automatic AI Vascular Intervention Surgical Robot Represents the Future Direction of Cardiovascular Interventional Treatment, Sparking Strong Interest from Indonesian Ministry of Health Leaders; Both Parties Conducted In-depth Exchanges on Product Technology Leadership, the Current State of Cardiovascular Interventional Treatment, and Future Clinical Application Prospects.
After the three founders of RaysightMed shared their insights, Dr. L. Rizka Andalucia, the Director General of Indonesia's Ministry of Health (MOH), introduced the registration and market access policies for medical device products in Indonesia. She stated that since last year, many guidelines have been formulated by Indonesia's healthcare sector.The innovative technology and cardiovascular precision diagnosis and treatment products of RaysightMed are impressive. It is hoped that RaysightMed can exchange with doctors and universities in Indonesia in the future, and explore new models of industry-university-research cooperation."The two parties had thorough discussions on key issues such as the product registration process, technical standard alignment, and clinical validation requirements, laying the groundwork for future cooperation."
Exhibition Hall Experience:
Experience the Innovative Charm of RaysightMed Products
After the meeting, Dr. L. Rizka Andalucia, Director General of Indonesia's Ministry of Health (MOH), and their delegation visited the RaysightMed exhibition hall. They observed live demonstrations of products such as RuiXin-FFR, AngioQFA, and the fully automatic AI vascular interventional surgical robot. Through an immersive experience, the leaders of Indonesia's Ministry of Health (MOH) expressed strong affirmation of the technological leadership and clinical application value of RaysightMed. Director General Dr. L. Rizka Andalucia stated:“RaysightMed's technological innovation is highly aligned with Indonesia's goals of enhancing medical accessibility and innovativeness. Both parties look forward to collaborating in the field of precision cardiovascular diagnosis and treatment.。”
Deepen Exchange:
Jointly Explore Market Access and Cooperation Prospects in Indonesia
The visit concluded with a dinner banquet, during which both parties reached an agreement on establishing a long-term cooperation mechanism. Zheng Lingxiao, founder and CEO of RaysightMed, stated that they would develop cardiovascular precision medical solutions tailored to local clinical needs based on Indonesia's market demands, supporting the intelligent upgrade of Indonesia's healthcare system.Dr. L. Rizka Andalucia, Director General of the Indonesian Ministry of Health (MOH)Also expressed welcome for innovative Chinese medical technology to be implemented in Indonesia.
This exchange marks a new phase in the medical technology cooperation between the two parties. In the future, RaysightMed will continue to deepen its international layout, empowering global precision cardiovascular healthcare with innovative technologies towards greater precision, intelligence, and automation.
